News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Panel Seeks Ban On Some Cox-2 Ads


10/19/2005 5:12:47 PM

A Food and Drug Administration advisory committee has recommended banning direct-to-consumer (DTC) advertising of cox-2 inhibitors after finding that the painkillers produced by Merck and Pfizer increased the risk of heart attacksand strokes. The FDA panel on Friday stopped short of banning Merck's Vioxx and Pfizer's Celebrex and Bextra but a majority recommended strong individually tailored -- black box -- warnings for the cardiovascular risk. A ban on cox-2 drugs DTC advertising was strongly urged by a consensus on the committee, which comprised 32 private medical experts. If a ban was not possible, the committee discussed regulatory measures including requiring advertisements devoted to risk warnings, or stronger placement of risk warnings in marketing.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES